Payment overview · 2025
General Payments
$365.59
11 reported records · 5 companies
Healthcare provider profile · identity verified
Maxine Orris, MD
Allopathic & Osteopathic Physicians|General Practice · BROOKLYN, NY · NPI 1720040702
Verified facts
What the public records show
CMS Open Payments records show Maxine Orris, MD received $365.59 in general payments during 2025 across 11 reported records.
Gilead Sciences, Inc. accounted for 44.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 147 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $163.89 | 44.8% | 7 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $125.00 | 34.2% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $33.00 | 9.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $24.62 | 6.7% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $19.08 | 5.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $365.59 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $33.00 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $24.62 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $24.62 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $19.08 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
48 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
104 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
147 | 30 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 656 | 176 |
| Metformin Hcl | Metformin Hcl | 510 | 133 |
| Amlodipine Besylate | Amlodipine Besylate | 486 | 127 |
| Lisinopril | Lisinopril | 283 | 85 |
| Losartan Potassium | Losartan Potassium | 272 | 72 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 258 | 77 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 224 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 221 | 58 |
| Simvastatin | Simvastatin | 196 | 60 |
| Levothyroxine Sodium | Levothyroxine Sodium | 190 | 55 |
| Hydrochlorothiazide | Hydrochlorothiazide | 182 | 52 |
| Gabapentin | Gabapentin | 174 | 52 |
| Januvia | Sitagliptin Phosphate | 174 | 34 |
| Omeprazole | Omeprazole | 169 | 43 |
| Furosemide | Furosemide | 163 | 43 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 152 | 41 |
| Trulicity | Dulaglutide | 147 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 143 | 41 |
| Ezetimibe | Ezetimibe | 133 | 36 |
| Famotidine | Famotidine | 129 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 126 | 37 |
| Montelukast Sodium | Montelukast Sodium | 119 | 39 |
| Meclizine Hcl | Meclizine Hcl | 118 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 117 | 30 |
| Pioglitazone Hcl | Pioglitazone Hcl | 111 | 29 |
| Jardiance | Empagliflozin | 104 | 30 |
| Carvedilol | Carvedilol | 103 | 24 |
| Eliquis | Apixaban | 103 | 22 |
| Diclofenac Sodium Er | Diclofenac Sodium | 101 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 101 | 27 |
| Nifedipine Er | Nifedipine | 98 | 30 |
| Diclofenac Sodium | Diclofenac Sodium | 97 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 88 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 87 | 21 |
| Single Use Swab | Alcohol Antiseptic Pads | 84 | 30 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 84 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 80 | 20 |
| Atenolol | Atenolol | 72 | 16 |
| Doxepin Hcl | Doxepin Hcl | 70 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 67 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 65 | 18 |
| Linzess | Linaclotide | 60 | 11 |
| Novolog Flexpen | Insulin Aspart | 59 | suppressed |
| Allopurinol | Allopurinol | 57 | 13 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 57 | 19 |
| Alendronate Sodium | Alendronate Sodium | 54 | 18 |
| Entresto | Sacubitril/Valsartan | 53 | 12 |
| Finasteride | Finasteride | 52 | 16 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 52 | 12 |
| Xarelto | Rivaroxaban | 52 | suppressed |
| Ibuprofen | Ibuprofen | 51 | 16 |
| Naproxen | Naproxen | 51 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 50 | 11 |
| Farxiga | Dapagliflozin Propanediol | 48 | 12 |
| Azelastine Hcl | Azelastine Hcl | 46 | suppressed |
| Chlorthalidone | Chlorthalidone | 46 | 14 |
| Vascepa | Icosapent Ethyl | 46 | suppressed |
| Acarbose | Acarbose | 45 | suppressed |
| Glimepiride | Glimepiride | 45 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | 11 |
| Trazodone Hcl | Trazodone Hcl | 43 | suppressed |
| Latanoprost | Latanoprost | 40 | 11 |
| Meloxicam | Meloxicam | 40 | 12 |
| Metformin Hcl Er | Metformin Hcl | 39 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 37 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 37 | suppressed |
| Ranolazine Er | Ranolazine | 37 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 34 | suppressed |
| Ketoconazole | Ketoconazole | 34 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 31 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 30 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 30 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | 17 |
| Levetiracetam | Levetiracetam | 28 | suppressed |
| Odefsey | Emtricitab/Rilpiviri/Tenof Ala | 28 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 28 | suppressed |
| Spironolactone | Spironolactone | 26 | suppressed |
| Ramipril | Ramipril | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 24 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Acyclovir | Acyclovir | 21 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Tradjenta | Linagliptin | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Ozempic | Semaglutide | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 18 | suppressed |
| Efavirenz-Emtric-Tenofov Disop | Efavirenz/Emtricit/Tenofovr Df | 18 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 17 | suppressed |
| Naproxen Sodium | Naproxen Sodium | 17 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 16 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 16 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 15 | suppressed |
| Potassium Chloride | Potassium Chloride | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Meloxicam | Meloxicam, Submicronized | 14 | suppressed |
| Alprazolam | Alprazolam | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 13 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 12 | suppressed |
| Naproxen-Esomeprazole Mag | Naproxen/Esomeprazole Mag | 12 | suppressed |
| Saxagliptin Hcl | Saxagliptin Hcl | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Ultra-Fine Original Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Haloperidol | Haloperidol | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Restasis | Cyclosporine | 11 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $365.59 · 11 records | Gilead Sciences, Inc. | AIRSUPRA, IBSRELA, LOREEV XR, MOUNJARO, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error